Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.

De Vriese AS, Caluwé R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, De Surgeloose D, Van Hoenacker P, Van Vlem B, Verbeke F.

J Am Soc Nephrol. 2019 Nov 8. pii: ASN.2019060579. doi: 10.1681/ASN.2019060579. [Epub ahead of print]

PMID:
31704740
2.

Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.

Bobart SA, De Vriese AS, Pawar AS, Zand L, Sethi S, Giesen C, Lieske JC, Fervenza FC.

Kidney Int. 2019 Feb;95(2):429-438. doi: 10.1016/j.kint.2018.10.021.

3.

Evaluation of vitamin K status and rationale for vitamin K supplementation in dialysis patients.

Caluwé R, Verbeke F, De Vriese AS.

Nephrol Dial Transplant. 2018 Dec 26. doi: 10.1093/ndt/gfy373. [Epub ahead of print]

PMID:
30590803
4.

C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.

Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S.

Mayo Clin Proc. 2018 Aug;93(8):991-1008. doi: 10.1016/j.mayocp.2018.05.019.

5.

Measurement of pulse wave velocity, augmentation index, and central pulse pressure in atrial fibrillation: a proof of concept study.

Caluwé R, De Vriese AS, Van Vlem B, Verbeke F.

J Am Soc Hypertens. 2018 Aug;12(8):627-632. doi: 10.1016/j.jash.2018.06.016. Epub 2018 Jun 30.

PMID:
30049625
6.

Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach.

De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC.

J Am Soc Nephrol. 2018 Mar;29(3):759-774. doi: 10.1681/ASN.2017090958. Epub 2018 Jan 10. Review.

7.

The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study.

Hommos MS, De Vriese AS, Alexander MP, Sethi S, Vaughan L, Zand L, Bharucha K, Lepori N, Rule AD, Fervenza FC.

Mayo Clin Proc. 2017 Dec;92(12):1772-1781. doi: 10.1016/j.mayocp.2017.09.011. Epub 2017 Oct 27.

8.

Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.

Geetha D, Sethi S, De Vriese AS, Specks U, Kallenberg CGM, Lim N, Spiera R, St Clair EW, Merkel PA, Seo P, Monach PA, Lepori N, Fessler BJ, Langford CA, Hoffman GS, Sharma R, Stone JH, Fervenza FC; RAVE-ITN Research Group.

Am J Nephrol. 2017;46(3):231-238. doi: 10.1159/000480443. Epub 2017 Sep 8.

9.

Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings
.

Angioi A, Cheungpasitporn W, Sethi S, De Vriese AS, Lepori N, Schwab TR, Fervenza FC.

Clin Nephrol. 2017 Nov;88(11):277-283. doi: 10.5414/CN109206.

PMID:
28853702
10.

Should Statins Be Banned from Dialysis?

De Vriese AS.

J Am Soc Nephrol. 2017 Jun;28(6):1675-1676. doi: 10.1681/ASN.2017020201. Epub 2017 May 3. Review. No abstract available.

11.

What are we missing in the clinical trials of focal segmental glomerulosclerosis?

Zand L, Glassock RJ, De Vriese AS, Sethi S, Fervenza FC.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i14-i21. doi: 10.1093/ndt/gfw324. Review.

PMID:
28391338
12.

Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis.

Sethi S, Zand L, De Vriese AS, Specks U, Vrana JA, Kanwar S, Kurtin P, Theis JD, Angioi A, Cornell L, Fervenza FC.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i139-i145. doi: 10.1093/ndt/gfw299.

PMID:
28391334
13.

A proposal for standardized grading of chronic changes in native kidney biopsy specimens.

Sethi S, D'Agati VD, Nast CC, Fogo AB, De Vriese AS, Markowitz GS, Glassock RJ, Fervenza FC, Seshan SV, Rule A, Racusen LC, Radhakrishnan J, Winearls CG, Appel GB, Bajema IM, Chang A, Colvin RB, Cook HT, Hariharan S, Herrera Hernandez LP, Kambham N, Mengel M, Nath KA, Rennke HG, Ronco P, Rovin BH, Haas M.

Kidney Int. 2017 Apr;91(4):787-789. doi: 10.1016/j.kint.2017.01.002.

PMID:
28314581
14.

Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.

Van Der Meersch H, De Bacquer D, De Vriese AS.

Am Heart J. 2017 Feb;184:37-46. doi: 10.1016/j.ahj.2016.09.016. Epub 2016 Oct 4. Review.

PMID:
27892885
15.

A Proposal for a Serology-Based Approach to Membranous Nephropathy.

De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC.

J Am Soc Nephrol. 2017 Feb;28(2):421-430. doi: 10.1681/ASN.2016070776. Epub 2016 Oct 24. Review.

16.

Temporal IgG Subtype Changes in Recurrent Idiopathic Membranous Nephropathy.

Kattah AG, Alexander MP, Angioi A, De Vriese AS, Sethi S, Cosio FG, Lorenz EC, Cornell LD, Fervenza FC.

Am J Transplant. 2016 Oct;16(10):2964-2972. doi: 10.1111/ajt.13806. Epub 2016 May 5.

17.

The atrial fibrillation conundrum in dialysis patients.

De Vriese AS, Caluwé R, Raggi P.

Am Heart J. 2016 Apr;174:111-9. doi: 10.1016/j.ahj.2016.01.010. Epub 2016 Jan 23. Review.

PMID:
26995377
18.

The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials.

Caluwé R, Pyfferoen L, De Boeck K, De Vriese AS.

Clin Kidney J. 2016 Apr;9(2):273-9. doi: 10.1093/ckj/sfv146. Epub 2015 Dec 29.

19.

Diagnosis of complement alternative pathway disorders.

Angioi A, Fervenza FC, Sethi S, Zhang Y, Smith RJ, Murray D, Van Praet J, Pani A, De Vriese AS.

Kidney Int. 2016 Feb;89(2):278-88. doi: 10.1016/j.kint.2015.12.003. Review.

PMID:
26806831
20.

Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Sethi S, Haas M, Markowitz GS, D'Agati VD, Rennke HG, Jennette JC, Bajema IM, Alpers CE, Chang A, Cornell LD, Cosio FG, Fogo AB, Glassock RJ, Hariharan S, Kambham N, Lager DJ, Leung N, Mengel M, Nath KA, Roberts IS, Rovin BH, Seshan SV, Smith RJ, Walker PD, Winearls CG, Appel GB, Alexander MP, Cattran DC, Casado CA, Cook HT, De Vriese AS, Radhakrishnan J, Racusen LC, Ronco P, Fervenza FC.

J Am Soc Nephrol. 2016 May;27(5):1278-87. doi: 10.1681/ASN.2015060612. Epub 2015 Nov 13.

21.

C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?

Alexander MP, Fervenza FC, De Vriese AS, Smith RJH, Nasr SH, Cornell LD, Herrera Hernandez LP, Zhang Y, Sethi S.

J Nephrol. 2016 Apr;29(2):203-209. doi: 10.1007/s40620-015-0218-9. Epub 2015 Jul 18.

PMID:
26187133
22.

Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC.

J Am Soc Nephrol. 2015 Dec;26(12):2917-29. doi: 10.1681/ASN.2015020184. Epub 2015 Jul 16. Review.

23.

High homocysteine induces betaine depletion.

Imbard A, Benoist JF, Esse R, Gupta S, Lebon S, de Vriese AS, de Baulny HO, Kruger W, Schiff M, Blom HJ.

Biosci Rep. 2015 Apr 28;35(4). pii: e00222. doi: 10.1042/BSR20150094.

24.

Opponent's comments.

De Vriese AS, Fervenza FC.

Nephrol Dial Transplant. 2015 Jun;30(6):898-9. doi: 10.1093/ndt/gfv108a. No abstract available.

PMID:
25994660
25.

Con: Biomarkers in glomerular diseases: putting the cart before the wheel?

De Vriese AS, Fervenza FC.

Nephrol Dial Transplant. 2015 Jun;30(6):885-90. doi: 10.1093/ndt/gfv107.

PMID:
25994657
26.

C4d as a Diagnostic Tool in Proliferative GN.

Sethi S, Nasr SH, De Vriese AS, Fervenza FC.

J Am Soc Nephrol. 2015 Nov;26(11):2852-9. doi: 10.1681/ASN.2014040406. Epub 2015 May 19.

27.

Dose-finding study of rivaroxaban in hemodialysis patients.

De Vriese AS, Caluwé R, Bailleul E, De Bacquer D, Borrey D, Van Vlem B, Vandecasteele SJ, Emmerechts J.

Am J Kidney Dis. 2015 Jul;66(1):91-8. doi: 10.1053/j.ajkd.2015.01.022. Epub 2015 Mar 21.

PMID:
25804678
28.

Hemodialysis catheter design and catheter performance: a randomized controlled trial.

Van Der Meersch H, De Bacquer D, Vandecasteele SJ, Van den Bergh B, Vermeiren P, De Letter J, De Vriese AS.

Am J Kidney Dis. 2014 Dec;64(6):902-8. doi: 10.1053/j.ajkd.2014.02.017. Epub 2014 Apr 6. Erratum in: Am J Kidney Dis. 2015 May;65(5):810.

PMID:
24713222
29.

Vancomycin: the tale of the vanquisher and the pyrrhic victory.

De Vriese AS, Vandecasteele SJ.

Perit Dial Int. 2014 Mar-Apr;34(2):154-61. doi: 10.3747/pdi.2014.00001.

30.

Cystatin C versus creatinine for kidney function-based risk.

Vandecasteele SJ, De Vriese AS.

N Engl J Med. 2013 Dec 19;369(25):2458-9. doi: 10.1056/NEJMc1312801. No abstract available.

PMID:
24350962
31.

Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study.

Caluwé R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS.

Nephrol Dial Transplant. 2014 Jul;29(7):1385-90. doi: 10.1093/ndt/gft464. Epub 2013 Nov 26.

PMID:
24285428
32.

Global protein and histone arginine methylation are affected in a tissue-specific manner in a rat model of diet-induced hyperhomocysteinemia.

Esse R, Florindo C, Imbard A, Rocha MS, de Vriese AS, Smulders YM, Teerlink T, Tavares de Almeida I, Castro R, Blom HJ.

Biochim Biophys Acta. 2013 Oct;1832(10):1708-14. doi: 10.1016/j.bbadis.2013.05.013. Epub 2013 May 22.

33.

The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties.

Vandecasteele SJ, De Vriese AS, Tacconelli E.

J Antimicrob Chemother. 2013 Apr;68(4):743-8. doi: 10.1093/jac/dks495. Epub 2012 Dec 18. Review.

PMID:
23249839
34.

Reversion of cerebral artery stenoses due to tuberculomas with TNF-α antibodies.

Vandecasteele SJ, De Vriese AS, Vanhooren GT.

Clin Neurol Neurosurg. 2012 Sep;114(7):1016-8. doi: 10.1016/j.clineuro.2012.01.027. Epub 2012 Feb 15. No abstract available.

PMID:
22341337
35.

Should we screen for coronary artery disease in asymptomatic chronic dialysis patients?

De Vriese AS, Vandecasteele SJ, Van den Bergh B, De Geeter FW.

Kidney Int. 2012 Jan;81(2):143-51. doi: 10.1038/ki.2011.340. Epub 2011 Sep 28. Review.

36.

Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 microg/mL in persons undergoing hemodialysis.

Vandecasteele SJ, De Bacquer D, De Vriese AS.

Clin Infect Dis. 2011 Jul 15;53(2):124-9. doi: 10.1093/cid/cir337.

PMID:
21690618
37.

Vancomycin dosing in patients on intermittent hemodialysis.

Vandecasteele SJ, De Vriese AS.

Semin Dial. 2011 Jan-Feb;24(1):50-5. doi: 10.1111/j.1525-139X.2010.00803.x. Review.

PMID:
21338394
38.

Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated alpha-2a interferon.

Vandecasteele SJ, De Paepe P, De Vriese AS.

Clin Nephrol. 2011 Feb;75 Suppl 1:1-3.

PMID:
21269584
39.

Recent changes in vancomycin use in renal failure.

Vandecasteele SJ, De Vriese AS.

Kidney Int. 2010 May;77(9):760-4. doi: 10.1038/ki.2010.35. Epub 2010 Feb 24. Review.

40.

Diffuse alveolar hemorrhage induced by everolimus.

Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS.

Chest. 2010 Feb;137(2):456-9. doi: 10.1378/chest.09-0780.

PMID:
20133293
41.

Staphylococcus aureus infections in hemodialysis: what a nephrologist should know.

Vandecasteele SJ, Boelaert JR, De Vriese AS.

Clin J Am Soc Nephrol. 2009 Aug;4(8):1388-400. doi: 10.2215/CJN.01590309. Epub 2009 Jul 9. Review.

42.

Comparison of the prognostic value of dipyridamole and dobutamine myocardial perfusion scintigraphy in hemodialysis patients.

De Vriese AS, De Bacquer DA, Verbeke FH, De Winter O, Franken PR, De Sutter JH, Walgraeve N, Missault L, De Geeter FW.

Kidney Int. 2009 Aug;76(4):428-36. doi: 10.1038/ki.2009.160. Epub 2009 Jun 3.

43.

Novel insights in the treatment of diabetic nephropathy.

Schrijvers BF, De Vriese AS.

Acta Clin Belg. 2007 Sep-Oct;62(5):278-90. Review.

PMID:
18229460
44.

Autologous transplantation of bone marrow mononuclear cells for limb ischemia in a caucasian population with atherosclerosis obliterans.

De Vriese AS, Billiet J, Van Droogenbroeck J, Ghekiere J, De Letter JA.

J Intern Med. 2008 Apr;263(4):395-403. doi: 10.1111/j.1365-2796.2007.01899.x. Epub 2008 Jan 21.

45.

Oral vitamin C administration increases lipid peroxidation in hemodialysis patients.

De Vriese AS, Borrey D, Mahieu E, Claeys I, Stevens L, Vanhaeverbeke A, Roelens M, Langlois MR.

Nephron Clin Pract. 2008;108(1):c28-34. Epub 2007 Dec 17.

PMID:
18087169
46.

Renal side effects of anti-VEGF therapy in man: a new test system.

Ostendorf T, De Vriese AS, Floege J.

Nephrol Dial Transplant. 2007 Oct;22(10):2778-80. Epub 2007 Jul 5. Review. No abstract available.

PMID:
17616538
47.

Prevention of contrast-induced nephropathy: a critical review.

Van Praet JT, De Vriese AS.

Curr Opin Nephrol Hypertens. 2007 Jul;16(4):336-47. Review.

PMID:
17565276
48.

Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: an in vivo study.

Geerts AM, Cheung KJ, Van Vlierberghe H, De Vriese AS, Mortier S, Vanheule E, Lameire N, De Vos M, Colle I.

J Hepatol. 2007 May;46(5):804-15. Epub 2006 Dec 15.

PMID:
17275128
49.

Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?

Denys BG, Bogaerts Y, Coenegrachts KL, De Vriese AS.

Clin Sci (Lond). 2007 Mar;112(5):281-9. Review.

PMID:
17261090
50.

Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients.

Blanckaert K, De Vriese AS.

Nephrol Dial Transplant. 2006 Dec;21(12):3364-7. Epub 2006 Sep 23. Review. No abstract available.

PMID:
16998219

Supplemental Content

Loading ...
Support Center